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Abstract 
Scope: Epidemiological evidence, animal and in vitro studies suggest that berry consumption may 
ameliorate markers of cardiovascular disease (CVD). The aim of this systematic review was to 
evaluate findings from berry-based randomised controlled trials (RCTs) to establish the effects of 
berry consumption on markers of cardiovascular and metabolic health.  
 
Methods and results: PubMed and Web of Science were searched for RCTs investigating berry 
consumption on CVD risk outcomes in adults. A total of 23 studies (which includes 1,168 
participants) out of 1,384 records met the inclusion criteria. Of these 23 studies, 17 RCTs were of 
high quality, where 12 RCTs (71%), reported beneficial effects of berry consumption on CVD risk 
markers. There were 4/11 RCTs that observed a reduction in systolic and/or diastolic blood pressure 
(BP); 3/7 RCTs reported favourable effects on endothelial function, 2/3 RCTs reported improvements 
in arterial stiffness, 7/17 studies observed benefits in blood lipids and 3/6 studies reported 
improvements in glycemic profile.  
 
Conclusion: Our evaluation of the literature indicates that more than two-thirds of high-quality trials 
have reported beneficial effects of berry consumption on markers of CVD risk. This systematic 
review contributes moderate to strong evidence for the inclusion of berries into a cardio-protective 
diet. 
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1. Introduction 
Cardiovascular disease (CVD) is the number one cause of mortality, accounting for 31% of all 
deaths worldwide [1]. Substantial personal and societal burden on the healthcare economy make CVD 
reduction a public health priority [2]. Diet is a cornerstone for the primary prevention of CVD [3]. 
Global dietary recommendations emphasise consumption of a diet rich in cardio-protective foods such 
as whole grains, fruit and vegetables, nuts and fish. Berries have gained strong recognition in recent 
times for their putative health benefits which has led to a 21% global increase in berry production [4, 
5]. Berries are a rich source of micronutrients and also contain bioactive components such as 
polyphenols, including anthocyanins, ellagitannins and flavonols [6].  
In the prospective Kuopio Ischemic Heart Disease Risk Factor study which consisted of 1,950 
men with no prior history of CVD events, men with the highest daily consumption of berries had a 
significantly lower risk of all-cause, CVD-related and non-CVD related mortality [risk ratio (RR) 0.66 
[95% confidence interval (CI) 0.50–0.88]] [7]. In the Iowa Women’s Health Study (IWHS), 
(n=34,489, postmenopausal women), strawberries were identified as one of the individual flavonoid-
rich foods associated with significant reductions in CVD-related mortality [8]. Data from animal [9] 
and in vitro [10]  models also suggest that berry-derived polyphenols may exert beneficial effects 
through their anti-oxidant, anti-inflammatory, anti-hypertensive and anti-lipidaemic activities which 
may prevent or attenuate atherosclerosis [11]. However, for these findings to be of clinical 
significance, they must be translated to well-designed randomised controlled trials (RCTs) in humans 
which clearly demonstrate cause and effect relationships.  
A recent meta-analysis reported that berry-based foods and berry-derived anthocyanin extracts 
were significantly associated with reductions in LDL-cholesterol, systolic blood pressure (BP), fasting 
glucose, body mass index, haemoglobin A1c and tumour necrosis factor-α [12]. However, the 
systematic review and meta-analysis by Huang et al., 2016, did not include endothelial function and 
arterial stiffness as outcomes which are emerging as important biomarkers of CVD risk [13, 14]. 
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Berries are not only a good source of anthocyanins but also contain other polyphenols such as 
ellagitannins which may exhibit independently or synergistically beneficial effects on markers of 
cardiovascular health [15, 16]. In addition, berries are sustainable, they can be easily grown, are 
pleasant tasting, and therefore, are recognised as a valuable fruit source which can be readily 
incorporated into the diet.  
The objective of this systematic narrative review was to investigate outcomes from RCTs using 
whole berry fruits or berry-based food products on markers of cardio-metabolic health.  Our primary 
outcomes included the effects of berry fruit consumption on blood pressure, endothelial function and 
arterial stiffness; while effects on blood lipids (to include oxLDL) and glucose concentrations were 
secondary outcomes.  
 
2. Materials and Methods 
 2.1 RCT eligibility criteria 
The review protocol was in accordance with PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines [17]. Full publications were included for evaluation subject 
to meeting the protocol criteria established a priori. The primary outcomes of this review were blood 
pressure, endothelial function and arterial stiffness while the secondary outcomes were blood lipids 
and glucose homeostasis.  
The inclusion criteria consisted of a human RCT which tested the effects of consuming either 
fresh whole berries or a berry-based product (eg. smoothie, juice) with a control group on at least one 
defined CVD related outcome (e.g. BP, arterial stiffness, blood lipids profile); with a study duration of 
≥4 weeks. Studies were excluded if participants were not randomised or if no control treatment was 
used. Studies were also excluded if they used a berry extract/capsule intervention; if they had a study 
duration <4 weeks or if the outcome of interest was not CVD-related.  No limits were placed on the 
type of study participants including sex, ethnicity or participants on medications.   
 
2.2 Search strategy 
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To develop the search strategy, we first defined a research question which assisted in the 
identification of key search terms. The online databases PubMed, Web of Science and Cochrane 
Library were utilised to search for articles related to our key terms, from their inception up until 
December 2016. Within the PubMed database, Medical Subject Headings (MeSH) terms were used 
where appropriate and a search history of generated records for each key term from each database was 
created (Supporting Information S1). Terms were combined using the Boolean logic “OR” which 
identified any articles containing one or more of those terms. The search results from each group were 
then combined using “AND” which generated articles containing berry terms, CVD markers and RCT 
design to be considered for the review. No limits were applied for language. The final search was run 
on 31st January 2017.   
 
2.3 Data extraction 
Articles generated as a result of the search in each online database were exported into the 
citation manager EndNote
©
 (2016 Thomson Reuters). Two investigators (CH and JL) independently 
screened the titles and abstracts that resulted from the search strategy (Figure 1). If disagreements 
arose they were resolved by consensus. References found within retrieved articles were also reviewed 
for potential relevant literature and one article was harvested in this manner. Data extracted included: 
the reference, study duration, intervention type, study design, description of study treatments, daily 
dose of treatment, total polyphenol dose, baseline value(s) for the CVD marker and significant 
findings. For articles with multiple interventions arms; findings relating to the comparison of the 
highest dose with the control arm were considered and presented.  One article lacked baseline data for 
the outcome of interest [18] and an attempt to contact the author was unsuccessful; therefore this 
article was not included.  
 
2.4 Quality assessment 
Articles were quality assessed using an adapted bias assessment tool developed by Jacobs and 
colleagues [19] which is in line with the Cochrane Collaboration’s tool for assessing risk of bias [20]. 
In this review, the tool was adapted to include criteria considered necessary for evaluation of a dietary 
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intervention study such as the assessment of compliance, background diet and study design [21, 22]. 
The articles generated were evaluated according to the criteria outlined in Supporting Information 
Table S2. For every criterion a RCT met, it was awarded an “A” score. The total of “A” scores 
achieved was then calculated to give a reflective representation of the quality of each RCT (Table 1). 
 
3. Results  
A total of 1,426 articles were identified from the online databases PubMed (n=863), Web of 
Science (n=359) and Cochrane Library (n=344) (Figure 1). After the removal of duplicates, 1,384 
articles remained. Titles and abstracts were screened resulting in a total of 60 RCTs considered 
eligible. After further evaluation, a final total of 23 RCTs were quality assessed and included in the 
review and are presented in Tables 2-5. These selected studies included a total of 1,168 adult 
participants. Cranberries (n=6), strawberries (n=5) and blueberries (n=5) were the main types of 
berries studied. Most studies (n=17) were conducted in participants at risk of CVD, such as adults 
with metabolic syndrome (n=5), hyperlipidemia (n=5) or hypertension (n=3), coronary artery disease 
(n=1), type 2 diabetes (n=1), insulin resistance (n=1), and smokers (n=1). The sample size of studies 
ranged from 18-71; with 11 RCTs having between 20 and 40 participants and one RCT with less than 
20 participants [23]. Compliance with treatments were quantified in 6/23 studies and ranged from 68-
100% [24-29].  
 
3.2 Characteristics of selected RCTs 
The majority of the selected RCTs in this systematic review were conducted in the USA 
(n=11); followed by Finland (n=5), Canada (n=2), Iran (n=2), Scotland (n=1), Sweden (n=1) and Italy 
(n=1). Of the 23 included RCTs, there were three RCTs [23, 30, 31] that recruited only male 
participants and two RCTs that included solely females [29, 32]. The selected RCTs had a mixture of 
sample populations including healthy (n=6), dyslipidemic (n=4), hypertensive (n=3), diabetic (n=1) or 
comprised of participants with coronary artery disease (n=1) or the metabolic syndrome (n=8). There 
were four of the selected RCTs each based in the USA that reported on the differentiation of ethnicity 
7 
 
in the sample population [26, 27, 33, 34]. Several of the selected RCTs contained participants that 
were taking medication during the study duration such as lipid-lowering drugs [35, 36], anti-
hypertensive agents [34-37], diabetic medication [38] or antiplatelet therapy [36]. Apart from two 
RCTs [28, 32], the included RCTs did not discriminate against whether female participants were pre- 
or postmenopausal. The study inclusion criterion of being a non-smoker was present in a number of 
RCTs (n=18) while other RCTs (n=5) incorporated both smokers and non-smokers into their sample 
population.       
3.3 RCT quality  
A summary of the RCT quality assessments applied are presented in Table 1. Of the 23 
RCTs, 17 studies achieved a total of 6 to 8 “A” scores out of a max score of 8. Nine RCTs were either 
single blinded, did not use a third party to assign randomisation and/or had insufficient allocation 
concealment [23, 25, 28, 30, 39-43].  In 7 RCTs, a control that was not identical in terms of 
appearance, taste and texture was used [25, 28, 30, 40-43]. Five studies did not provide information 
on the characterisation of the study products in terms of nutrient and polyphenol profiles [28, 30, 41, 
42, 44]. 
Two studies did not evaluate compliance with the study treatment [31, 41]. Of those that did 
evaluate participant compliance, 4 studies included a biomarker of exposure such as plasma quercetin 
[43], plasma vitamin C [45], plasma ellagic acid [24] and urinary polyphenol metabolites [39]. In 
terms of attrition, three studies failed to report dropouts [27, 32, 35], while 3 other studies reported a 
dropout rate > 20% [25, 42, 44]. 
 
3.4 Effect of berry consumption on blood pressure 
Eleven RCTs investigated BP as an outcome (Table 2). Out of these, 4 studies reported 
significant reductions in BP from baseline [32, 33, 39, 43] for systolic BP. A mixed berry intervention 
study reported significant reduction in systolic BP in adults with elevated BP (-1%) [43]; while a 
blueberry beverage intervention reported a more substantial reduction in hypertensive females (-5%) 
[32] when compared to the control groups. A chokeberry intervention reported a reduction in 
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ambulatory diastolic day BP readings (-2%) in adults with elevated BP [39], while a blueberry 
intervention reported a 6% reduction in diastolic BP in hypertensive females [32]. Similarly, a 
cranberry juice intervention also reported a 6% reduction in diastolic BP in normotensive adults [33]. 
These findings support that reductions in systolic BP may be linked to a higher baseline systolic BP 
while diastolic BP reductions appear more likely to be independent of baseline BP measures.   
However, two of the RCTs reporting reductions in BP were single-blinded [39, 43]. In the 
chokeberry intervention, the authors reported a significant increase in urinary excretion of potassium 
in the treatment group compared with control [39]. In the mixed berry intervention [43], a 
significantly higher plasma vitamin C concentration was reported in the berry group compared to the 
control group; the control was a selection of products (sugar water, semolina porridge, rice porridge 
and marmalade sweets) and did not have a similar micronutrient profile to the treatment therefore, 
potential for bias must considered. 
 
3.5 Effect of berry consumption on endothelial function and arterial stiffness 
Endothelial function was measured by FMD (n=2) while arterial stiffness was measured 
using pulse wave velocity (PWV) (n=2) and augmentation index (AIx) (n=1) in studies (Table 3a). 
Markers of endothelial dysfunction, vascular cell adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1) concentrations were studied in 4 RCTs (Table 3b). Of the RCTs 
investigating FMD as a measurement of endothelial function, one study observed a significant 
improvement (+19%) in FMD in healthy adults over 6 weeks [45]. In the 2 RCTs that investigated 
arterial stiffness, a significant reduction in carotid-femoral PWV (-0.5m/s or 6%) was observed by 
Dohadwala et al. (2011) after a cranberry intervention and a reduction in brachial-ankle PWV (-0.93 
or 6%) was reported by Johnson et al. (2015) after a blueberry intervention. There was no effect of 
consuming a cranberry drink on arterial stiffness as measured by AIx [31]. No significant reductions 
in ICAM-1 and VCAM-1 concentrations were reported in 3 RCTs following a cranberry (n=2) or a 
strawberry intervention [24, 33, 35]. However, Basu et al. (2010) observed an 18% reduction in 
plasma VCAM-1 concentrations post a strawberry beverage intervention with no changes in ICAM-1 
when compared with the control group [37]. 
9 
 
 
3.6 Effect of berry consumption and lipid profile 
Seventeen studies (Table 4) investigated the effect of berry consumption on blood lipids 
including total cholesterol (n=16), HDL cholesterol (n=16), LDL cholesterol (n=13), triglycerides 
(TAG) (n=14) and oxidised LDL (oxLDL) (n=3) were identified. The study populations from the 
RCTs included in this review consisted of dyslipidaemic, hypertensive, metabolic syndrome, healthy 
adults and adults with coronary artery disease. Ten RCTs found no significant effects on circulating 
blood lipids [26-28, 31, 35, 39-42, 46]. In addition, there was a large variation in the mean (SD) ages 
of the participants which may have further contributed to heterogeneity and variability in study 
findings.  
For total cholesterol, three strawberry intervention studies reported a significant reduction in 
concentrations of between 7 and 15% [24, 37, 44] however, the strawberry intervention had an 
attrition rate of 32% [44] which is substantially higher than the 20% attrition threshold associated with 
bias in clinical trials [47]. 
Interestingly, two further strawberry intervention studies reported a significant mean 
reduction in LDL cholesterol after 12 weeks (21%) and 8 weeks (11%) [24, 37]. One study with 
mixed berries observed a 5% increase in mean circulating HDL after 4 weeks [43]. Of the 3 studies 
that investigated oxLDL [29, 31, 48], there was a significant 33% reduction in mean plasma oxLDL 
concentrations after an 8-week cranberry intervention in adults with metabolic syndrome [29]; a 6-
week crossover strawberry intervention in hyperlipidemic adults reported a significant mean reduction 
in postprandial concentrations of oxLDL (-7.7U/L) in response to a high-fat meal, when adjusted for 
baseline oxLDL [48]; while a 4-week  cranberry intervention in healthy adults reported no change in 
oxLDL concentrations.   
 
3.7 Berry consumption and blood glucose 
Six studies out of the twenty-three studies included fasting blood glucose, insulin and/or the 
homeostatic assessment model of insulin resistance (HOMA-IR) as an outcome (Table 5)[24, 25, 27, 
30, 33, 39]. Three RCTs observed no significant changes on fasting glucose and insulin 
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concentrations or HOMA-IR [24, 25, 39]. Two studies involving a cranberry juice intervention 
observed significant reductions in fasting glucose concentrations in type 2 diabetic patients (-13%) 
after 12 weeks [30] and in healthy adults (-2%) after 8 weeks [33]. While Stull et al (2010) observed 
no significant change in glucose or insulin concentrations after a 6-week blueberry intervention, a 
significant improvement in insulin sensitivity among 67% of participants in the blueberry treatment 
group compared with a 41% improvement in the placebo group using a hyperinsulinaemic euglycemic 
clamp was observed.   
 
3.8 Reported adverse Effects 
Aside from two RCTs that advised participants to record any potential adverse effects in a 
food diary [27, 39], it appears that in general, adverse effects were not considered or reported 
systematically in accordance with good clinical practice. In a blackcurrant RCT, Khan and colleagues 
reported the loss of a study participant due to diarrhea and a further six participants that completed 
this blackcurrant juice intervention reported indigestion, loose bowel movements and increased 
urinary frequency [45]. Similarly, gastrointestinal discomfort was reported as the main reason for non-
compliance in a blueberry RCT in hypertensive females [32]. In a separate cranberry juice 
intervention, two participants withdrew from a due to dyspepsia [26].   
 
4. Discussion 
The evidence from the RCTs described in this systematic narrative review is largely supportive of the 
hypothesis that the consumption of berries has the potential to have an effect on multiple 
cardiovascular outcomes including BP, blood lipid profiles, vascular endothelial function and 
glycemic profile. This systematic review differs from the previous meta-analysis by Huang et al. 
(2016)[12]in that it has exclusively focused on RCTs which have used whole berries or berry-based 
food products as an intervention on markers of cardio-metabolic health, with an objective to evaluate 
whether the consumption of berries or berry-based food products should be encouraged in the diet to 
improve cardio-metabolic health. The cardiovascular outcomes: Endothelial function and Arterial 
stiffness have also been included within the scope of this review.  
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 Of the 17 studies that were considered high quality (achieving between 6 and 8 “A” scores in 
the quality evaluation), 13 reported a positive effect on at least one marker of cardiovascular risk. 
Dietary intervention studies are frequently faced with challenges in relation to aspects of their study 
design e.g. background diet, matched control, assessment of compliance, this was apparent in the 
current review and further contributes to the large inter-individual variation and the heterogeneity in 
study findings that is being increasingly reported in polyphenol-based dietary intervention studies.  In 
addition, it is concerning that participant safety and the reporting of adverse events were prioritised in 
only two of the 23 studies. 
Hypertension is defined as a BP reading ≥140 systolic mmHg and ≥90 diastolic mmHg [49]. 
The findings of the current chapter show reductions in BP in four studies, which are promising. 
However, our findings do not support a specific berry type or study duration that is more 
advantageous at lowering BP. Findings from in vitro studies indicate that berries may reduce BP 
through the inhibition of the potent vasoconstrictor, angiotensin converting enzyme [50]. In a 
subgroup analysis by Erlund et al. (2008), the greatest reductions in BP were observed in those with 
the highest baseline BP and therefore small BP lowering margins in normotensive populations may 
explain the null findings in studies conducted in normotensive populations [43]. In the current review 
as the mean baseline BP was normotensive in three RCTs, reductions were not statistically or 
clinically significant [23, 28, 40]. Also, a recent Cochrane meta-analysis of cocoa polyphenols and BP 
reported a trend that BP reduction may not be as efficient in older adults [51]. In the current chapter, 
there is insufficient evidence to indicate a dose-response relationship between berry-based polyphenol 
intakes and BP as neither systolic BP or diastolic BP were further reduced with increasing polyphenol 
intakes. Future studies investigating associations between berry consumption and BP should be 
inclusive of adults with elevated BP and hypertensive populations.  
Endothelial dysfunction is a major hallmark of atherosclerosis [52] as arterial walls become 
injured due to high BP or oxidative stress [35]. FMD is currently the gold standard method for the 
measurement of endothelial function [53]. Vascular ageing is linked to endothelial dysfunction [13] 
and arterial stiffness can be determined through the measurement of PWV and AIx [54]. Several 
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polyphenol based interventions, as summarised in a meta-analysis conducted by Hooper et al. (2012) 
and a recent systematic review [55] support positive effects of polyphenol consumption on endothelial 
function however, outcomes measures of endothelial function have been less studied in berry 
interventions to date [56]. In the current chapter, six RCTs investigated endothelial function [34, 37, 
45] and three RCTs included arterial stiffness as study outcomes. Of these, one study reported positive 
significant effects of berry consumption on endothelial function, where FMD increased by 19% [45]. 
Two studies reported positive benefits to arterial stiffness with reductions of 6% in PWV [26, 32]. As 
there are promising results from polyphenol-based RCTs, endothelial function and arterial stiffness 
are outcomes that should be considered for investigation in future berry intervention studies.  
In berry-based RCTs to date, blood lipid profiles have been frequently included as a primary 
outcome [57]. Berries may have favourable effects on blood lipids due to putative mechanisms such 
as their ability to increase HDL and reduce LDL cholesterol through the inhibition of cholesteryl ester 
transfer protein, a protein which transfers cholesteryl esters from HDL to proatherogenic 
apolipoprotein B lipoproteins by berry-derived polyphenols such as anthocyanins [58]. Of the 17 
RCTs in this review which measured blood lipids as an outcome, only one RCT [43] reported a 
significant increase in HDL cholesterol concentrations which is in agreement with the findings of the 
meta-analysis by Huang et al. (2016).  
In the current review, six out of 17 RCTs observed significant reductions in total cholesterol, 
LDL cholesterol, triglycerides and oxidised LDL concentrations. Interestingly, out of a total of five 
strawberry interventions, four observed clinically significant reductions in circulating total 
cholesterol, LDL cholesterol, triglyceride and oxidised LDL concentrations [24, 37, 44, 48]. It should 
be noted that these strawberry interventions were well-designed RCTs on the basis of achieving at 
least 7 “A” scores out of a total of 8 quality scores. Interestingly, one study did not find a significant 
effect on blood lipid profile when fresh strawberries (450g/d) were used instead of processed 
strawberry treatments [28]. This highlights that the berry type and food matrix in which the berries are 
ingested may impact their physiological efficacy in vivo. These findings indicate that the beneficial 
effects of strawberry consumption on CVD risk may be partially attributable to their lipid-lowering 
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abilities and indicates a clear requirement for future trials which will impart knowledge on choice of 
study sample, dose response, study duration, the design of study treatments and potential mechanisms 
of action.  
Among diabetic patients, cardiovascular disease is the main cause of mortality, accounting for 
70% of deaths [59]. Incidences of type 2 diabetes are concomitantly on the rise with the increasing 
rates of global obesity [60]. In the current chapter, out of a total of 6 RCTs, 1 trial investigated 
glucose and insulin homeostasis as a primary outcome [27]. Cranberry juice and blueberry 
interventions demonstrated favourable effects on glycemic profile in three well-controlled studies [27, 
30, 33], which supports the hypothesis that berry consumption may reduce blood glucose 
concentrations, particularly in diabetic individuals and substantially improve insulin sensitivity in 
insulin resistant adults. Future studies should explore the potential effects of berries in glucose and 
insulin homeostasis as a primary outcome in populations with diabetes or impaired glucose tolerance. 
In terms of assessing the quality of these berry-based dietary interventions, the lack of a 
placebo control and insufficient concealment of treatment allocation were the main criteria most 
frequently not achieved in our analysis. The creation of a true placebo, free of polyphenols but 
matched in terms of colour, taste and appearance is a persistent obstacle for the designing of berry-
based RCTs [56]. It is also worth noting that the health benefits demonstrated in berry-based RCTs 
may not be solely attributable to polyphenols but other berry components such as nutrients. Therefore, 
it is important that potential confounding influences such as intrinsic nutrients including fibre, 
potassium and vitamin C are considered and addressed through the use of a matched placebo [56].  
As polyphenols are present in a variety of foods within the diet, the potential effects of 
background diet must also be accounted for [61]. Background diet can be controlled to an extent in 
free-living individuals through the creation of a restricted foods list or can be quantified through food 
diaries or food frequency questionnaires [62]. In addition to assessing adherence to a restricted foods 
list, it is also necessary to assess compliance to the prescribed intervention. Most of the RCTs 
included in this review included an assessment of compliance within their study protocol. Examples 
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of compliance assessments included counting of unused bottles/sachets, analysis of food diaries and 
face to face or telephone interviews. However, to fully ensure accurate and valid assessment of 
compliance with the consumption of study treatments, an appropriate biomarker of exposure is 
recommended. Three of the included RCTs used a biomarker of exposure such as plasma 
concentrations of vitamin C [45], urinary polyphenol metabolites [39] and plasma concentrations of 
polyphenols such as quercetin [43]. To date, the measurement of polyphenols such as flavonoids, 
which are present in abundance in berries, has proved challenging due to their short half-life in 
circulation (<6-8 hours) [63]. Ideally, instead of using one biomarker of exposure in a polyphenol-
based RCT, a metabolomic profile of the treatment, containing data relating to the metabolites and 
their corresponding polyphenol precursors should be considered [64, 65]. The identification of this 
metabolic profile in plasma or urine samples collected in the study may be more specific to the 
treatment and thus, a more robust biomarker of exposure.  
This comprehensive review has provided a clear evaluation of the effects of berry-based 
interventions on markers of CVD risk, has included a rigorous assessment of bias for the 
determination of study quality, and has focused on defined cardiovascular outcomes. However, the 
design of the search strategy that was applied in this systematic review may have excluded potential 
important markers of cardio-metabolic risk such as inflammatory markers. To date there have been a 
limited number of berry-based interventions conducted and therefore no limitations were applied as 
regards the type of study population and may not be applicable to either the general population or a 
individuals with a particular condition (e.g diabetes) and therefore a possible limitation of this 
systematic review.   
 We did not reveal an optimal treatment duration, as positive effects were observed in studies 
of both 4 and 12 weeks duration for all outcomes. In addition, while there was an absence of dose 
response trials in the current review, higher polyphenol and anthocyanin intakes did not appear to 
provide an additive beneficial effect on health outcomes. Optimal dosing, effective methods of 
administration, use of whole food versus extracts/supplements and the profiling of berry polyphenols 
to specific health outcomes remain to be investigated [65, 66].  
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Future studies should endeavor to elucidate the potential effects of berry consumption on 
surrogate markers of CVD, including endothelial function and arterial stiffness as outcomes, as well 
as emerging markers of cardio-metabolic health such as inflammatory markers and markers of 
oxidative stress and glucose using appropriate study designs that have considered the identified 
knowledge gaps to advance research and elucidate the potential cardio-protective effects of berries 
[67]. In addition, the safety of berry interventions should be addressed through a systematic approach 
of reporting potential adverse events according to good clinical practice. A recently developed, freely 
available toolkit providing guidance for the design and execution of dietary intervention studies could 
prove a practical resource for the development of future berry-based food interventions [21].  This 
review has presented a considerable amount of evidence to support the consumption of berries for 
cardio-protective effects on endothelial function, arterial stiffness, LDL cholesterol and oxidised 
LDL. High rates of compliance (68-100%) with the berry treatments were reported across RCTs 
which indicates that the addition of berries to the diet is well accepted with few reported adverse 
effects. Taking these findings into consideration, the consumption of berries should be extensively 
encouraged as part of a cardio-protective diet.  
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Table 1. Quality assessment of included RCTs 
 
                                        
Reference Treatment 
blinding 
Allocation 
concealment 
Baseline 
Comparability 
Sample 
Number 
Drop outs Results 
presentation 
Compliance  Intervention dose Number of A 
scores 
(out of 8) 
Novotny et al. 2015 A A A A A A A A 8 
Stull et al. 2015 A A A A A A A A 8 
Basu et al. 2014 A A A A A A A A 8 
Khan et al.2014  A A A A A A A A 8 
Larmo et al. 2009 A A A A A A A A 8 
Dohadwala et al. 2011 A A A A A A A A 8 
Johnson et al. 2015 A A A A B A A A 7 
Basu et al. 2011 A A A B A A A A 7 
Basu et al. 2010C A A A B A A A A 7 
Burton-Freeman et al. 2010 A A A B A A A A 7 
Stull et al. 2010 A A A B A A A A 7 
Aghababaee et al. 2015  C C A A A A A A 6 
Flammer et al. 2013 A A C A B A A A 6 
Riso et al.2013 A B A C A A A A 6 
Shidfar et al. 2012 B A A A A A A C 6 
Erlund et al. 2008 B C A A A A A A 6 
Ruel et al. 2013 A A A B A A C A 6 
Loo et al. 2016 B B A B A A A A 5 
Zunino et al. 2012 A A A B C A A C 5 
Kolehmainen et al. 2012 C C A B C A A A 4 
Jenkins et al.2008 B C A B A A A B 4 
Nyberg et al. 2013 C C A B A A C C 3 
Puuponen-pimia et al. 2013 C C A B C A A B 3 
Table 1: Randomised controlled trials investigating berry consumption and BP as an outcome. 
 
 
Table 2: Randomised controlled trials investigating berry consumption and blood pressure as an 
outcome. 
 
 
Table 1: Randomised controlled trials investigating berry consumption and blood pressure as an 
outcome. 
 
 
Table 2: Randomised controlled trials investigating berry consumption and blood pressure as an 
outcome. 
 
Treatment blinding: Was study single or double-blinded? Allocation concealment: Was the treatment and control matched in appearance, taste and texture? Baseline 
comparability: Were the comparison groups matched in terms of gender, ethnicity, smokers and medication users? Sample number: Was the sample size ≤20, 20-40 or ≥40? Drop 
outs: Was the attrition rate <20%, unreported or <20%? Results presentation: Are results presented in a clear manner and the authors have made appropriate conclusions based on 
the findings? Compliance: Was there an assessment of compliance in the study? Intervention dose: Are the treatment and controls appropriately characterised?   
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Table 2 Randomised controlled trials investigating berry consumption and blood pressure as an outcome 
 
a) Crossover, b) Parallel, c) Systolic blood pressure,  d) Diastolic blood pressure, e) Anthocyanins,  f)  High dose, g) Low dose , h) Not reported, i) Primary outcome, j) Secondary outcome 
Reference Year RCT participants 
(n) 
Mean Age 
Years 
(SD) 
Duratio
n 
(weeks) 
Study 
Design 
Intervention Control Daily dose Total phenol dose 
(mg)/day 
Baseline 
SBPc)/DBPd) 
(mmHg) 
Significant BP 
Findings 
(mmHg) 
Loo 
 
2016 Elevated BP adults 
(37) 
55 (NR) 8 Ca) Chokeberry 
juice 
Placebo 300ml 2194 
ACNse): 1024 
Resting: 133/83 
24-h Ambulatory: 129/85 
Day: 135/89 
Night: 115/76 
 
↓Day DBP (2%)i) 
Aghababaee 2015 Dyslipidemic 
adults 
(72) 
45(8) 8 Pb) Blackberry 
drink 
Usual diet 300ml 948 122/81 No change 
Stull 
 
2015 Metabolic 
syndrome adults 
(44) 
55(2) 6 P Blueberry 
smoothie 
Placebo 680g 773 
ACNs: 290 
 
Resting: 126/83 
24-h Ambulatory: 123/79 
No changei) 
Johnson 
 
2015 Hypertensive 
females 
(48) 
60(5) 8 P Blueberry 
beverage 
Placebo 480ml 845 
ACNs:469 
138/80 ↓SBP (5.1%)i) 
↓DBP (6.3%) 
Novotny 
 
2015 Healthy adults 
(60) 
50(11) 8 P Cranberry juice Placebo 480ml 346 
ACNs:21 
122/74 ↓DBP (6%) 
Basu 
 
2014 Hyperlipidemic 
adults 
(60) 
49(10) 12 P Strawberry 
beverage 
 
Placebo 474ml HDf): 2005 
LDg): 1001 
 
HD (136/86) 
LD (128/83) 
 
No change 
Khan 2014 Healthy adults 
(66) 
Low dose 
55 (10) 
High dose 
51 (11) 
6 P Blackcurrant 
juice 
Placebo 1L 
(250mlx4) 
HD: 820 
LD: 270 
 
HD (127/79) 
LD (130/82) 
 
No changej) 
Riso 
 
2012 Male smokers 
(18) 
48(8) 6 C Blueberry 
beverage 
Placebo 250ml ACNs: 375 121/79 No changei) 
Dohadwala 
 
2011 Coronary artery 
disease adults 
(44) 
62(10) 4 C Cranberry juice Placebo 250ml 835 
ACNs: 94 
131/77 No changej) 
Erlund 
 
2008 Elevated BP adults 
(71) 
58(6) 4 P Mixed berries, 
purée, 
juice 
Placebo Fresh(100g) 
Puree(100g) 
Juice (70ml) 
837 128/80 ↓SBP (1%) 
 
Jenkins 
 
2008 Hyperlipidemic 
adults 
(30) 
62(1) 4 C Fresh 
strawberries 
Oat bran 
bread 
454g NRh) 111/68 
 
No BP changej) 
Table 4: Randomised controlled trials investigating berry consumption and metabolic profile as an outcome. 
 
 
Table 6: Randomised controlled trials investigating berry consumption and metabolic profile as an outcome. 
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Table 3 (a) Randomised controlled trials investigating berry consumption on endothelial function and arterial stiffness as an outcome 
Reference Year RCT participants 
(n) 
Mean Age 
Years (SD) 
Duration 
(weeks) 
Study 
design 
Intervention Control Daily dose 
(ml) 
Total phenol 
dose 
(mg/d) 
Baseline 
PWVc) 
(m/s) 
Baseline 
FMDd) 
(%) 
Baseline 
RHIe) 
Findings 
 
Stull 2015 Metabolic syndrome 
adults 
(44) 
55(2) 6 Pa) Blueberry 
smoothie 
Placebo 680 773 
ACNsf): 290 
 
NR NR 1.94 Change in 
magnitude of RHI 
response 
(0.23 vs -0.23)n) 
Johnson 
 
 
2015 Hypertensive females 
(48) 
60(5) 8 P Blueberry 
beverage 
Placebo 480 845 
ACNs:469 
CfPWV:12.3 
BaPWV:15.0 
NR NR No change in 
CfPWVg) 
↓BaPWVh) (6%)n) 
Khan 
 
2014 Healthy adults 
(64) 
Low dose 
55(10) 
High dose 
51(11) 
6 P Blackcurrant 
juice drink 
Placebo 1000 HD: 820 
LD: 270 
 
NR 5.8 NR ↑FMD 
(19%)m) 
Ruel 
 
2013 Healthy males 
(35) 
45(10) 4 Cb) Cranberry juice Placebo 500 400 
ACNs :20.8 
NR NR* NR No change on AIx m) 
Flammer 2013 CVD risk adults 
(69) 
50(16) 16 P Cranberry juice Placebo 460 800 
ACNs:69 
 
NR NR* NR No significant effect 
on FMD 
Dohadwala 
 
2011 Coronary artery 
disease adults 
(44) 
62(10) 4 C Cranberry juice Placebo 250 835 
ACNs:94 
8.3 6.3 NR No significant effect 
on FMD 
↓PWV (6%)m) 
 
a) Parallel, b) Crossover, c) Pulse wave velocity, d) Flow mediated dilation, e) Reactive hyperemia index, f) Anthocyanins,  g) Carotid-femoral pulse wave velocity,   h) Brachial-ankle pulse wave velocity, i) 
High dose, j) Low dose,  k) Augmentation index, l) Not reported , m) Primary outcome, n) Secondary outcome 
 33 
 
Table 3 (b) Randomised controlled trials investigating berry consumption on ICAM-1 and VCAM-1 as biomarkers of endothelial dysfunction  
 
a) Parallel b) Vascular cell adhesion molecule-1, c) Intercellular adhesion molecule-1 (ICAM-1), d) Anthocyanins, e) Carotid-femoral pulse wave velocity, f) Brachial-ankle pulse wave velocity, g) High dose, h) Low dose, i) 
Augmentation index, j) Not reported, k) Primary outcome, l) Secondary outcome 
Reference Year RCT participants 
(n) 
Mean 
Age 
Years (SD) 
Duration 
(weeks) 
Study design Intervention Control Daily dose 
(ml) 
Total 
phenol dose 
(mg/d) 
Baseline 
VCAM-1 
(ng/ml) 
Baseline 
ICAM-1 
(ng/ml) 
Findings 
 
Flammer 2013 CVD risk adults 
(69) 
50(16) 16 Pa) Cranberry juice Placebo 460 800 
ACNsd): 69 
 
535 189 No significant effect 
on VCAM-1b) / 
ICAM-1c) 
Novotny 2015 Healthy adults 
(60) 
50(11) 8 P Cranberry juice Placebo 480 346 
ACNs: 21 
444 263 No significant effect 
on VCAM-1/ 
ICAM-1 
Basu 
 
2014 Hyperlipidemic 
adults 
(60) 
49(10) 12 P Strawberry beverage Placebo 474 HD: 2005 
LD: 1001 
 
 
HD: 610 
LD: 709 
 
HD : 256 
LD: 258 
 
No significant effect 
on VCAM-1 /ICAM-
1 
Basu 
 
2010 Metabolic 
syndrome patients 
(27) 
47(3) 8 P Strawberry beverage Water 960 2006 
ACNs: 154 
273 294 No significant effect 
on ICAM-1 
↓VCAM-1(18%) 
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Table 4 Randomised controlled trials investigating berry consumption on blood lipid profile as an outcome 
Reference  
 
Year  RCT 
participants 
(n) 
 
Mean 
Age 
Years 
(SD) 
Duration 
(weeks) 
Study 
design  
Intervention Control Daily dose Total phenol 
dose 
(mg) 
Baseline 
TCHOL 
(mmol/L) 
Baseline LDL 
d)(mmol/L) 
Baseline 
HDLe) 
(mmol/L) 
Baseline 
TAGf) 
(mmol/L) 
Baseline 
oxLDLg) 
(U/L) 
Findings 
Loo  
 
2016 Elevated BP 
adults  
(37) 
55(NR) 8 Ca) Chokeberry 
juice 
Placebo 300ml 2194 
ACNsh) : 
1024 
5.2 NRk) 1.68 1.09 NR* No changel) 
Aghababaee  2015 Dyslipidemic 
adults 
 (72) 
45(8) 8 Pb) Blackberry 
juice 
Usual diet 300ml 964 5.79 3.10 0.99 2.63 NR* No change 
Novotny 
 
2015 Healthy adults 
(60) 
50(11) 8 P Cranberry juice Placebo 480ml 346 
ACNs: 21 
5.00 3.21 1.19 1.28 NR* ↓TAG 
(10%) 
Basu  
 
2014 Hyperlipidemic  
adults 
(60) 
49(10) 12 P Strawberry 
beverage 
Placebo 474ml HDi): 2005 
LDj): 1001 
 
HD: 5.53 
LD: 5.20 
HD: 3.36 
LD: 3.10 
HD: 1.27 
LD: 1.22 
HD: 1.95 
LD: 1.73 
NR* ↓TCHOLc) 
(15%) 
↓ LDL 
(21%) 
Nyberg  
 
2013 Healthy adults 
(26) 
28(7) 8 C Blueberries Usual diet 150g NR* NR* 2.86 1.50 0.94 NR* No change 
Puupponen-
Pimia  
2013 Metabolic 
syndrome 
(32) 
NR* 8 P Mixed fresh 
and frozen 
berries 
Usual diet  300g ACNs: 71 5.60 3.70 1.40 NR* NR* No change 
Ruel  
 
2013 Healthy males 
(35) 
45(10) 4 C Cranberry juice Placebo 500ml 400 
ACNs: 20.8 
5.33 3.51 1.19 1.54 64.3 No changel) 
 
Flammer  
 
2012 CVD risk adults 
(69) 
50(16) 16 P Cranberry juice Placebo  460ml 800 
ACNs: 69 
4.65 NR* 1.24 2.25 NR* No change 
a) Crossover, b) Parallel, c) Total cholesterol, d) Low density lipoprotein), e) High density lipoprotein, f) Triglycerides, g) Oxidised LDL, h) Anthocyanins, i) High dose), j) Low dose, k) Not reported, l) Secondary 
outcome 
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Table 4 continued Randomised controlled trials investigating berry consumption and lipid profile as an outcome 
a) Crossover, b) Parallel, c) Total cholesterol, d) Low density lipoprotein  e) High density lipoprotein, f) Triglycerides, g) Oxidised LDL, h) Not reported i) Anthocyanins, j) Primary outcome, k) Secondary outcome 
Reference 
 
Year RCT 
participants 
(n) 
 
Mean Age 
Years (SD) 
Duration 
(weeks) 
Study 
design 
Intervention Control Daily dose Total 
phenol 
dose 
(mg) 
Baseline 
TCHOLc) 
(mmol/L) 
Baseline 
LDLd) 
(mmol/L) 
Baseline 
HDLe) 
(mmol/L) 
Baseline 
TAGf) 
(mmol/L) 
Baseline 
oxLDLg) 
(U/L) 
Findings 
Zunino 
 
2012 Healthy adults 
(27) 
F:32(11) 
M:29(7) 
7 Ca) Strawberry 
powder 
Placebo 320g NRh) 4.72 NR NR NR NR ↓TCHOL 
(7%)j) 
Basu 
 
2011 Metabolic 
syndrome 
(36) 
52(8) 8 Pb) Cranberry 
beverage 
Placebo 480ml 458 
ACNsi): 
24.8 
5.22 3.54 1.24 1.58 120 ↓ oxLDL 
(33%) 
Dohadwala 2011 Coronary artery 
disease adults 
(44) 
62(10) 4 C Cranberry 
juice 
Placebo 250ml 835 
ACNs: 94 
4.08 2.30 1.11 3.36 NR No changek) 
Basu 
 
2010 Metabolic 
syndrome 
patients 
(27) 
47(3) 8 P Strawberry 
beverage 
Water 960ml 2006 
ACNs: 154 
5.80 3.50 1.20 1.60 NR ↓TCHOL 
(10%) 
↓LDL 
(11%) 
Burton-
Freeman 
 
2010 Hyperlipidemic 
adults                         
(24) 
51(15) 6 C Strawberry 
beverage 
Placebo 305g 338 5.43 3.67 1.27 2.67 NR ↓TAG 
(3%) 
↓postprandial 
oxLDL 
responsej) 
Stull 
 
2010 Insulin resistant 
adults 
(32) 
54(3) 6 P Blueberry 
smoothie 
Placebo 757g 1462 
ACNs:668 
5.34 3.28 1.35 1.53 NR No changek) 
Larmo 
 
2009 Healthy adults 
(229) 
31(7) 12 P Sea buckthorn 
purée 
Placebo 28g NR 4.98 2.87 1.57 NR NR No changej) 
Erlund 
 
2008 Elevated BP 
adults 
(71) 
58(6) 4 P Mixed berries, 
purée, 
juice 
Placebo Fresh(100g) 
puree(100g) 
juice (70ml) 
837 6.30 NR 1.50 1.60 NR Increase in HDL 
(5%) 
Jenkins 
 
2008 Hyperlipidemic 
adults 
(28) 
62(1) 4 C Fresh 
strawberries 
Oat bran 
bread 
450g NR 5.62 3.61 1.36 1.43 NR No changej) 
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Table 5 Randomised controlled trials investigating berry consumption and metabolic profile as an outcome 
a)Crossover, b) Parallel, c) Homeostatic model assessment of insulin resistance, d) Anthocyanins, e) High dose , f) Low dose, g) Not reported, h) Primary outcome, i) Secondary outcome 
 
 
Reference Year RCT 
participants 
(n) 
Mean Age 
Years (SD) 
Duration 
(weeks) 
Study 
design  
 
Intervention Control  Daily dose 
 
Total phenol 
dose 
(mg) 
Baseline 
Glucose 
(mmol/L) 
Baseline 
Insulin 
(pmol/L) 
Baseline 
HOMA-IRc) 
Findings 
Loo  
 
2016 Elevated BP 
adults 
(37) 
55(NR) 8 Ca) Chokeberry 
juice 
Placebo 300ml  2194 
ACNsd) : 1024 
5.25 NRg) NR No change in glucose 
concentrationsI) 
Novotny  
 
2015 Healthy adults  
(60) 
50(11) 8 Pb) Cranberry 
juice 
Placebo 480ml 346  
ACNs: 21 
5.42 53.02 1.8 ↓ Fasting glucose 
(2%) 
 ↓HOMA-IR (2%) 
Basu  
 
2014 Hyperlipidemic 
adults 
(60) 
49(10) 12 P Strawberry 
beverage 
Placebo 474ml HDe): 2005 
LDf): 1001 
 
HD: 5.2 
LD: 5.5 
 
HD: 115 
LD: 136 
 
HD: 3.8 
LD: 4.9 
 
 No change in glucose, insulin 
or HOMA-IR 
Kolehmainen 
 
2012 Metabolic 
syndrome adults 
(27) 
53(6) 8 P Bilberry puree 
& 
Dried 
Bilberries 
Usual diet  240g ACNs 
Puree: 524 
Dried: 832 
 
6.1 NR NR No change in  glucose and 
insulin concentrations 
Shidfar  
 
2012 Type 2 diabetic 
males 
(58) 
55(9) 12 P Cranberry 
juice 
Placebo 240ml NR 7.7 NR NR ↓ Fasting glucose 
(13%) 
Stull  
 
2010 Obese and 
insulin resistant 
adults 
(32) 
54(3) 6  P Blueberry 
beverage 
Placebo 757g 1462 
ACNs:668 
5.7 132 NR Increase in insulin sensitivity  
(22%) 
No change in glucose and 
insulin concentrationsh) 
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